Significance: Preventing the aggregation of toxic proteins in neurodegenerative diseases is both an important biological function and a potential therapeutic strategy. Here, we examine the consequences of O-GlcNAcylation on the aggregation and toxicity of α-synuclein, the aggregating protein in Parkinson’s disease. α-Synuclein is modified by O-GlcNAc at at least nine different positions in vivo, but the consequences of most of these modifications are unknown. Here, we use synthetic protein chemistry to prepare six different O-GlcNAcylated forms of α-synuclein and show that they have largely inhibitory, but site-specific, effects on the aggregation and cellular toxicity of this protein. These results suggest that O-GlcNAc may be a cellular strategy to prevent protein aggregation, which could potentially be exploited for treatment.